Figure 3.
Time-to-event analyses. (A) OS in CMML and MDS. (B) Event-free survival by diagnosis. (C) OS by TP53 status. (D) Landmark analysis at median time to transplant for patients who underwent allo-HSCT.
Time-to-event analyses. (A) OS in CMML and MDS. (B) Event-free survival by diagnosis. (C) OS by TP53 status. (D) Landmark analysis at median time to transplant for patients who underwent allo-HSCT.
